B7/CD28 Costimulation of T Cells Induces a Distinct Proteome Pattern*

Kai Kronfeld{ddagger},§, Elisabeth Hochleitner, Simone Mendler{ddagger},||, Jutta Goldschmidt{ddagger}, Rudolf Lichtenfels{ddagger},**, Friedrich Lottspeich, Hinrich Abken{ddagger}{ddagger} and Barbara Seliger{ddagger},**,§§

From the {ddagger} IIIrd Department of Internal Medicine, Johannes Gutenberg University, 55131 Mainz, Germany, § Coordination Centre for Clinical Trials (Koordinationzentrum für Klinische Studien Mainz), Johannes Gutenberg University, 55131 Mainz, Germany, Max Planck Institute for Biochemistry, 82152 Martinsried, Germany, || Department of Otorhinolaryngology, Johannes Gutenberg University, 55131 Mainz, Germany, {ddagger}{ddagger} Department I of Internal Medicine, Tumor Genetics and Centre of Molecular Medicine Cologne, University of Cologne, 50924 Cologne, Germany, and ** Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle, Germany


    ABSTRACT
 TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Effective immune strategies for the eradication of human tumors require a detailed understanding of the interaction of tumor cells with the immune system, which might lead to an optimization of T cell responses. To understand the impact of B7-mediated costimulation on T cell activation comprehensive proteome analysis of B7-primed T cell populations were performed. Using this approach we identified different classes of proteins in T cells whose expression is either elevated or reduced upon B7-1- or B7-2-mediated CD28 costimulation. The altered proteins include regulators of the cell cycle and cell proliferation, signal transducers, components of the antigen processing machinery, transporters, cytoskeletal proteins, and metabolic enzymes. A number of differentially expressed proteins are further modified by phosphorylation. Our results provide novel insights into the complexity of the CD28 costimulatory pathway of T cells and will help to identify potential targets of therapeutic interventions for modulating anti-tumor T cell activation.


Effective T cell activation requires the engagement of two separate signals. The first is mediated by the interaction of the T cell receptor (TCR)1 complex with MHC class I-peptide complexes. The second signal is dependent on the interaction of various cell surface receptors on T cells and their ligands typically expressed on antigen-presenting cells providing essential costimulatory signals. These costimulatory signals are pivotal in determining whether recognition of antigen by T cells leads to full T cell activation, T cell anergy, or apoptosis (1, 2).

The best studied costimulatory pathway is represented by the CD28/CTLA4-B7 system (2, 3) where B7-1 (CD80) and B7-2 (CD86) bind either to an activating (CD28) or to an inhibitory (CTLA4) receptor on T cells (4). A variety of studies demonstrate the significance of CD28 costimulation in the clonal expansion of naïve T cells, the regulation of long term survival of T cells, induction of cell cycle progression, and cytokine secretion (5). The elucidation of the CD28-mediated functions has facilitated the development of therapeutic strategies, particularly vaccination studies, that target this pathway. Most efforts to induce antigen-specific immunity by application of cancer vaccines have focused on the generation of tumor-reactive CD8+ cytotoxic T cells (CTLs) (6). Whereas B7-negative tumor cells most often fail to induce an efficient immune response, B7-1 and/or B7-2 expression on tumor cells augments the anti-tumor response by inducing T cell proliferation, cytokine secretion, and an enhanced generation of tumor-specific CD8+ CTLs (710). B7-transduced renal cell carcinoma cells are an example of the strategy to stimulate tumor-infiltrating T cells to promote an efficient antitumor response (11, 12).

The efficacy of an antitumor reaction is usually monitored by in vitro determination of the number of antigen-specific T cells that secrete cytokines in response to antigen challenge. The monitoring can be achieved by enzyme-linked immunospot techniques (13, 14), flow cytometry (15), multiplex-based immunoassays (16) or RT-PCR (17). Such assays, however, do not provide any information regarding the various signaling and metabolic pathways activated upon CD28 costimulation of the T cell. Particularly only limited information on the genetic expression programs linked to CD28 costimulation exists (1820), whereas to our best knowledge no study to date has assessed the protein expression patterns of both prestimulated and naïve T cells upon CD28 costimulation. To address the complexity of the T cell response directed against a defined, B7-transduced tumor cell vaccine, here we applied proteome-based technologies and identified a variety of differentially expressed proteins in T cells following B7-1 and B7-2 costimulation, respectively. Some of these proteins additionally exhibit altered phosphorylation patterns. The studies provide novel insights into the biology of the B7/CD28 signal transduction pathway as well as early steps in the induction of an antitumor T cell response.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Isolation and Stimulation of T Cells—
Peripheral blood mononuclear cells were isolated from buffy coats of healthy HLA-A2+ donors by Ficoll Hypaque (Amersham Biosciences) density gradient centrifugation. Peripheral blood mononuclear cells were prestimulated for 5 days with the anti-CD3 antibody OKT3 (500 ng/ml) (Orthoclon, Janssen-Cilag, Neuss, Germany) and recombinant human interleukin (IL)-2 (250 units/ml) (Proleukin, Roche Diagnostics). After prestimulation, more than 95% of cells express CD3 as determined by flow cytometry. Cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) autologous plasma, 2 mM L-glutamine, 10 IU/ml penicillin, 100 µg/ml streptomycin, 10 mM sodium pyruvate, 100 mM Hepes, and 1x non-essential amino acids (Invitrogen).

Cell Lines and Tissue Culture—
The renal cell carcinoma line MZ1257RC was established from a primary tumor lesion of an HLA-A2+ patient with renal cell carcinoma (12, 21). MZ1257RC cells were equipped with B7-1 and B7-2, respectively, by DNA transfection as described previously (12, 22). MZ1257RC cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 10 IU/ml penicillin, 100 µg/ml streptomycin, 10 mM sodium pyruvate, 100 mM Hepes, and 1x non-essential amino acids. Transfected cells were cultivated in the presence of 400 µg/ml G418.

Mixed Lymphocyte Reactions—
OKT3 monoclonal antibody plus IL-2-prestimulated T cells were incubated with MZ1257RC cells that had been fixed for 15 min with 1% (w/v) paraformaldehyde at an effector to target ratio of 1:10. After 48 h T cell proliferation was determined using an MTS (3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt) assay (Cell Titer 96, Promega, Mannheim, Germany). T cell supernatants were analyzed for interferon-{gamma}, tumor necrosis factor-{alpha}, IL-10, and granulocyte macrophage colony-stimulating factor by ELISA (BD Pharmingen). T cells were subjected to proteome and RT-PCR analyses.

Isolation of Phosphoproteins—
Phosphoproteins were isolated from T cells using the Phosphoprotein Purification kit (Qiagen, Hilden, Germany) as recommended by the manufacturer. This kit is designed for the specific purification of all phosphorylated proteins from complex cell lysates. Briefly 2.5 x 107 cells were lysed in lysis buffer containing detergent, nucleases, and protease inhibitors. Lysates were cleared by centrifugation (90 min at 13,000 rpm at 15 °C), and the supernatants were loaded onto phosphoprotein-specific columns for affinity chromatography. The eluted proteins were concentrated using Nanosep ultrafiltration columns (Pall, Dreieich, Germany).

Proteome Analyses—
Protein lysates (300 µg of total protein lysates and 100 µg of phosphoprotein fraction, respectively) were loaded onto IPG strips (Immobiline dry strips, pH 3–10, non-linear, Amersham Biosciences). Isoelectric focusing, second dimension SDS-PAGE separation, silver staining, and gel documentation was performed as described previously (23). The gels were analyzed using the Proteomweaver software package (Version 2.0, Definiens, Munich, Germany). Proteins were subjected to further analyses when the given protein spot was found to be altered in at least three of five gels and the differences in the expression levels was at least 2-fold. Furthermore spots were analyzed when a different position compared with the corresponding spot from T cells coincubated with MZ1257RC cells was observed. Protein spots of interest were excised from the respective gel, digested with the endoproteinase Lys-C (Roche Diagnostics), and subjected to mass analysis using positive reflector mode with a deflection cutoff range of m/z 800 on a 4700 Proteomics Analyzer (Applied Biosystems, Framingham, MA). Subsequently high energy MALDI-TOF/TOF CID spectra were recorded on selected ions from the same sample spot. For the unambiguous identification of the proteins, tandem mass spectrometric analyses were performed on one or two peptides of the corresponding peptide mass fingerprints and annotated by MASCOT using the National Center for Biotechnology Information (NCBI) protein database (www.matrixscience.com). For protein classification into functional clusters the website ncbi.nlm.nih.gov/entrez/querey.fcgi?db=PubMed was used.

RT-PCR and Western Blot Analyses—
Total RNA from T cells was isolated using the RNeasy kit (Qiagen) according to the manufacturer’s instructions, and the RNA was subjected to RT-PCR analyses (Titan kit, Roche Applied Science) using the sets of gene-specific primer oligonucleotides listed in Table I.


View this table:
[in this window]
[in a new window]
 
TABLE I Primer oligonucleotides used in this study

 
Western blot analyses were performed as described recently (23) using monoclonal antibodies directed against stathmin (Calbiochem), proliferative cellular nuclear antigen (PCNA) (Santa Cruz Biotechnology, Heidelberg, Germany), and ß-actin (Abcam, Cambridge, UK), respectively. The immunostainings were visualized using the ECL chemoluminescence detection kit (Amersham Biosciences).


    RESULTS
 TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
T Cells Express an Altered Pattern of Proteins upon B7 Costimulation—
We wanted to identify T cell proteins whose expression is altered upon contact of activated T cells with tumor cells that express B7-1 and B7-2, respectively. T cells obtained from two unrelated HLA-A2+ volunteers were preactivated by incubation with the anti-CD3 monoclonal antibody OKT3 and IL-2. T cells were coincubated with paraformaldehyde-fixed wild-type (wt) MZ1257RC cells, B7-1- and B7-2-modified MZ1257RC cells, or MZ1257RC cells transfected with "empty" vector DNA. Cells of the B7-transduced MZ1257RC clones express about 1.25 x 106 B7-1 and B7-2 molecules/cell, respectively (22). Upon coincubation with either B7-1+ or B7-2+ MZ1257RC cells T cells increased proliferation and cytokine secretion (interferon-{gamma}, granulocyte macrophage colony-stimulating factor, tumor necrosis factor-{alpha}, and IL-10), whereas coincubation with wt and mock-transfected MZ1257RC cells did not (data not shown). T cells were lysed and subjected to two-dimensional gel electrophoresis (2-DE) as described under "Experimental Procedures" after 48-h costimulation with B7-transduced and control cells. The data were obtained from two independent sets of proteome analyses and are based on five gels per sample. Representative 2-D gel spot patterns are shown in Fig. 1. Routinely about 1,500 protein spots per gel were detected. In samples from T cells costimulated via B7-1 or B7-2, respectively, 35 protein spots with quantitatively altered expression patterns were found from which 15 spots are increased while 20 spots are decreased in intensity. It is noteworthy that seven proteins are altered in expression upon B7-1 and 13 proteins are altered in expression upon B7-2 costimulation, whereas 15 of the differentially expressed proteins are similarly altered in expression upon both B7-1 and B7-2 costimulation. Additionally 10 proteins show a modified expression upon both B7-1 and B7-2 costimulation as characterized by a different position compared with the corresponding spot from T cells coincubated with wt MZ1257RC cells. The identity of 35 of 45 differentially expressed proteins was determined by mass spectroscopy. A representative mass spectrometry analysis is shown for the glia maturation factor-{gamma} in Fig. 2 demonstrating the peptide mass fingerprinting (Fig. 2A) and the verification of the fingerprinting results by MS/MS analysis. The proteins as well as their physical properties are summarized in Table II. The differentially expressed proteins include metabolic enzymes, components of the antigen processing machinery, transporters, and cytoskeletal proteins as well as cell cycle and cell proliferation regulators. In addition, proteins with yet unknown functions in T cells were identified.



View larger version (94K):
[in this window]
[in a new window]
 
FIG. 1. Representative 2-D electrophoresis gels of protein lysates from T cells coincubated with MZ1257RC cells without B7 expression (A) and with B7-2+ MZ1257RC cells (B) for 48 h. Proteins were separated using non-linear pH gradients (pH 3–10) in the first dimension. Zoomed sections of the representative gels are shown in C. Protein spots with differences in the protein expression patterns of gel A compared with B are marked (upper panel). The identities of the individual spots were determined by mass spectrometry. n.i. = not identified (C).

 


View larger version (23K):
[in this window]
[in a new window]
 
FIG. 2. Representative mass spectrometry analysis. A protein spot of interest was excised from a gel, processed as described under "Experimental Procedures," and digested with endoproteinase Lys-C. The resulting peptide fragments were subsequently analyzed by mass spectrometry. The resulting fingerprint comprised several fragments in the range of 899–4013 Da is shown in A. As indicated the x axis represents the mass to charge ratios (m/z), whereas the y axis represents the given peak intensities. The interpretation of the fragment pattern led to the identification of the glia maturation factor-{gamma}. To verify the peptide mass fingerprinting of the glia maturation factor-{gamma} the fragment with the molecular mass of 2194 Da was further characterized by MS/MS analysis. Its fragmentation led to the identification of the protein sequence VFEIRTTDDLTEAWLQEK covering the stretch of amino acids 120–137 within the target protein (B).

 

View this table:
[in this window]
[in a new window]
 
TABLE II T cell proteins with altered expression upon B7-1- and B7-2-mediated costimulation

T cells were coincubated for 24 h with paraformaldehyde-fixed MZ1257RC cells and MZ1257RC cells transfected with B7-1 and B7-2, respectively. Protein lysates from T cells were subjected to 2-D gel electrophoresis as described under 'Experimental Procedures.' Protein expression patterns of T cells coincubated with B7-1+ and B7-2+ MZ1257RC cells were compared with those of T cells coincubated with MZ1257RC cells lacking B7 expression. The identities of the individual protein spots were determined by mass spectrometry. N.A., expression level not altered compared to stimulation with wt_MZ1257RC cells; >, expression level increased; <, expression level decreased; phospho, protein is phosphorylated; modified, protein spot is at a different position compared to the corresponding spot from T cells coincubated with MZ1257RC cells. ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; PKC, protein kinase C; GDI, GDP dissociation inhibitor.

 
Altered Phosphorylation Pattern of Differentially Expressed Proteins in T Cells upon B7 Costimulation—
We monitored alterations in the phosphorylation patterns of proteins in T cells upon B7-1 and B7-2-mediated costimulation after 15 min, 60 min, and 24 h. Upon 60 min of stimulation 2-D gel analyses of phosphoprotein subproteome revealed 288 phosphorylated protein spots (Fig. 3A). From these, 248 protein spots are phosphorylated upon both B7-1- and B7-2-mediated costimulation. In contrast, five proteins are only phosphorylated upon B7-1 costimulation alone, and 35 proteins are phosphorylated upon B7-2 stimulation of T cells (Fig. 3B). From these differentially phosphorylated protein spots, 24 proteins could be identified by mass spectroscopy (Table II). Most of these phosphorylated proteins belong to components of the antigen processing machinery in particular to subunits of the proteasome complex.



View larger version (103K):
[in this window]
[in a new window]
 
FIG. 3. Distinct time-dependent pattern of phosphoprotein expressions in T cells upon B7-1 and B7-2 costimulation. T cells were coincubated for 15 min, 60 min, and 24 h with paraformaldehyde-fixed B7-1+ and B7-2+ MZ1257RC cells and without MZ1257RC cells as control. Phosphoproteins from T cells were separated by 2-D gel electrophoresis (A). Zoomed regions of 2-D gels of phosphoproteins obtained from T cells without and upon coincubation with B7-1+ and B7-2+ MZ1257RC cells are demonstrated in B. An arrow marks the protein spot that decreases after B7-1 and B7-2 stimulation. Protein spots marked with a circle show differences in expression upon B7-1- and B7-2-mediated costimulation, respectively.

 
Validation of the Differentially Expressed Proteins—
RT-PCR and Western blot analyses were used to validate a selected number of differentially expressed proteins in T cells upon B7 costimulation. Some of the validation results are shown exemplarily in Fig. 4. For all proteins analyzed, the B7 costimulation-associated expression alterations detected by proteomics were confirmed by Western blot and/or RT-PCR. For example, the PCNA was confirmed by both RT-PCR and Western blot analysis to be increased in expression upon both B7-1 and B7-2 costimulation. The expression of stathmin, a ubiquitously expressed, highly conserved cytoplasmic protein (24, 25), was increased upon B7-1 and B7-2 costimulation by 2-DE analysis, which was confirmed by RT-PCR and Western blot analyses (Fig. 4). Phosphoproteome analysis revealed increased stathmin phosphorylation upon B7 costimulation (Table II). Loss of expression of the platelet-derived growth factor (PDGF)-binding protein in T cells upon stimulation with B7 was identified by 2-DE analysis and confirmed by RT-PCR (Fig. 4). Nudix hydrolase-5 (nudt5), which catalyzes the hydrolysis of ADP-ribose and ADP-mannose (26), is significantly down-regulated in expression upon costimulation with B7-1 but not with B7-2. RT-PCR analysis confirmed reduced amounts of nudt5 mRNA in B7-1 but not in B7-2 costimulated T cells (Fig. 4).



View larger version (37K):
[in this window]
[in a new window]
 
FIG. 4. Validation of differentially expressed proteins in T cells upon B7-1 and B7-2 costimulation as monitored by RT-PCR and Western blot analysis. T cells were coincubated for 48 h with paraformaldehyde-fixed wild type MZ1257RC cells, MZ1257RC vector control cells (mock-transfected controls) and B7-1+ or B7-2+ MZ1257RC cells, respectively (A). Total cellular RNA was isolated and subjected to RT-PCR analysis as described under "Experimental Procedures" (B). Proteins were monitored by Western blot analyses.

 

    DISCUSSION
 TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
T cell activation by costimulatory pathways is a key issue in T cell immunology and in T cell-based immunotherapy. The detailed knowledge of their signal transduction pathways has a significant impact on the design of therapies for autoimmune diseases, transplantation, and tumors. T cells stimulated by antigen receptors, cytokines, or chemokines trigger an independent array of signaling molecules including the activation of different kinases as well as other molecules involved in cellular metabolism, cell growth and maintenance, differentiation, and other cellular processes. Some novel components of the signaling network have been identified recently by transcriptome and proteome analysis of activated CD4+ and CD8+ T lymphocytes, undifferentiated T cells, and antigen receptor-activated T cells as well as Jurkat cells (1820, 2731). In contrast, only little information exists on the effects of CD28 costimulation on the global gene transcription program of T cells (1820). Using cDNA microarray analysis of T cells triggered via TCR and/or costimulatory receptors, a large series of differentially expressed mRNAs has been identified (20), whereas the protein expression profile of T cells under CD28 costimulatory conditions has not yet been investigated. Therefore, the CD28 costimulation-mediated alterations in the protein expression pattern and their contributions to T cell stimulation are so far poorly understood. Because T cell activation involves changes in the signal transduction that are often associated with posttranscriptional modifications such as phosphorylation, both the global proteome and phosphoproteome analyses represent the first step toward elucidating the mechanisms by which B7-1 and B7-2 costimulation alters the antitumor response. Due to the high number of T cells required for proteome analysis and the few changes found in the mRNA expression pattern following stimulation of naïve T cells (20), the use of naïve T cells in this approach is experimentally challenging. Therefore, here we focused on the analysis of prestimulated T cells upon coincubation with wt, mock-transfected, and B7-1- or B7-2-transfected MZ1257RC cells using proteome-based technologies to identify proteins with altered protein expression patterns under these conditions. However, it is noteworthy that this state of the art analysis still has some practical limitations mainly based on the scarce material available for proteomics. The analyses indicate that upon incubation with B7-1+ and B7-2+ MZ1257RC cells CD28 costimulation of T cells induces distinct alterations in the global protein expression as well as in the protein phosphorylation patterns. 45 proteins were differentially expressed upon B7 costimulation, and 288 proteins exhibit an altered phosphorylation pattern (Table II). In this study, we found 15 proteins that are up-regulated and 20 proteins that are down-regulated upon B7 costimulation indicating a distinct translational program associated with CD28 costimulation of T cells. Although the majority of the differentially expressed proteins are similarly regulated upon B7-1 and B7-2 stimulation, certain proteins are exclusively altered in response to either the B7-1- (seven proteins identified) or B7-2 (13 proteins identified)-mediated CD28 costimulation, also further underlining the distinct function of both molecules in the costimulation process (32, 33). In addition, phosphoproteome analyses revealed a distinct and time-dependent alteration in the protein phosphorylation pattern of T cells stimulated with wild-type or B7-transduced MZ1257RC cells. These results suggest that changes in the phosphorylation of a broad set of proteins are required for efficient T cell activation. The majority of proteins, however, are phosphorylated in a similar fashion 60 min after onset of B7-1 and B7-2 costimulation. However, in this context it is even noteworthy that the paraformaldehyde-fixed tumor cells may cause an underestimation of the effect of B7-2 because B7-2 but not B7-1 is affected by paraformaldehyde fixation (34).

The proteins differentially expressed and/or phosphorylated upon CD28 costimulation of T cells are involved in controlling cell proliferation, apoptosis, antigen processing, transport, signal transduction, cellular metabolism including various energy pathways, protein degradation, cytoskeleton formation, and the immunological synapse (Table II). In addition, proteins with yet unknown functions were altered in their expression under these conditions. Their identification might give further insights into the B7/CD28 signal transduction pathway. In comparison to cDNA microarray data, there exists an overlap with our proteome data regarding the differentially expressed gene/protein families. However, the changes identified on a single gene/protein are mainly not overlapping. This might be due to the limited number of differentially expressed proteins analyzed as well as to the often observed posttranscriptional modifications that appear to be important for T cell signal transduction.

Because T cell activation is known to be closely associated with enhanced proliferation and consequently with increased PCNA levels (35), the detection of increased amounts of PCNA protein in T cells upon stimulation with B7-1- and B7-2-transduced MZ1257RC cells by proteome analysis served as an internal standard and, on the other hand, indicates the proof of principle for the experimental procedure. Regarding proteins involved in metabolism, our data are in accordance with Frauwirth et al. (36) who demonstrated that CD28 costimulation increases the glucose metabolism allowing T cells to meet their energetic and biosynthetic needs associated with a sustained response.

To validate some of the differentially expressed proteins, e.g. PCNA, stathmin, nudix hydrolase-5, and PDGF-binding protein, we applied both Western blot and RT-PCR analyses. Stathmin was found to be one of the up-regulated proteins in T cells upon both B7-1- and B7-2-mediated CD28 costimulation. Stathmin integrates a series of intracellular signals (24, 25). Its expression and phosphorylation are regulated by extracellular signals mediating proliferation and/or differentiation. In line with our results, a distinct CD28 costimulation-dependent pattern of stathmin phosphorylation has been reported in the context of T cell activation (37). Ca2+/calmodulin-dependent kinase II is associated with costimulatory signals of T lymphocyte activation and phosphorylation of stathmin on Ser-16 (37). In contrast to stathmin, expression of the PDGF-binding protein is decreased upon CD28 costimulation. PDGF-binding protein was found to be differentially expressed upon B7/CD28 costimulation. It is a physiological inducer of the nuclear factor of activated T cells (NFAT) that is substantially involved in Ca2+-dependent gene transcription processes in immune cells (38). Furthermore the CD28 pathway is important for IL-4 production, which involves NFAT members. The PDGF-binding protein enhances the PDGF-A-mediated stimulation of cell proliferation but inhibits the mitogenic effect of PDGF-B (39, 40). Thus, decreased PDGF-binding protein expression upon B7-mediated T cell activation may be linked to increased T cell proliferation by withdrawal of the inhibitory activity toward PDGF-B.

Nudix hydrolase-5 is found to be down-regulated in T cells after CD28 costimulation exclusively via B7-1 but not via B7-2. Proteins of the superfamily of nudix hydrolases catalyze the hydrolysis of a panel of nucleoside-diphosphate derivatives and are therefore involved in the cellular nucleotide metabolism. To our best knowledge nudix hydrolase has never been described in the context of T lymphocytes. Cyclin D1 (4144) is in the center of a network involved in cell cycle control, interacting directly with PCNA and GST Pi (4547). PCNA, the RNA-binding subunit (4851), and the Ras family protein Ran (5255) interact with the androgen receptor, modulating its signal transduction activities (5660). The Rho GDP dissociation inhibitor (61, 62), the Raf kinase inhibitor (6366), prefoldin-5 interacting with c-Myc (67, 68), the glia maturation factor (6769), and stathmin are linked to the Ras/Raf/mitogen-activated protein kinase pathway involved in c-Myc activation, suggesting that these proteins are involved in the synapse formation. However, it has been noted that no cytokines have been identified by this approach. This might be due to the low intracellular levels and might be enhanced by brefeldin A treatment of T cells.

The functional consequences of this distinct protein expression pattern need further investigation. The expression pattern, however, clearly points to shared but also distinct activities of B7-1- and B7-2-mediated CD28 costimulation as reported earlier (7072). The differentially expressed proteins identified to be altered in expression and/or phosphorylation upon B7-1- and B7-2-mediated stimulation suggest their involvement in T cell activation in general, whereas the differentially expressed proteins point to differences in the B7-1 and B7-2 costimulatory pathway. Interestingly the majority of posttranslational modifications are the same upon B7-1 and B7-2 costimulation.

Although most of the proteins associated with B7 costimulation have been found in T lymphocytes, there is only limited information available on the network of the potential protein/protein interactions and their regulations. A putative model illustrating the signaling pathways that describe the costimulatory pathways should include the alterations in protein expression and phosphorylation as described here. The results of the proteome-based analysis enable a more solid interpretation of the alterations in protein expression during costimulation-mediated T cell activation. Despite this overall screen, our analysis identified a distinct set of proteins with potential significance in B7-mediated costimulation. It is noteworthy that the protein informations obtained by this strategy may also have some drawbacks because the protein expression pattern may additionally differ in particular T cell repertoires and the specific TCR/MHC engagement. The experimental approach described here and the knowledge drawn from the survey, however, may also contribute to identify new therapeutic targets within the CD28 costimulatory pathway and to develop therapeutic agents capable to manipulate T cell responses.


    ACKNOWLEDGMENTS
 
We thank Liis Pellenen for excellent secretarial help.


   FOOTNOTES
 
Received, June 29, 2005, and in revised form, August 16, 2005.

Published, MCP Papers in Press, August 19, 2005, DOI 10.1074/mcp.M500194-MCP200

1 The abbreviations used are: TCR, T cell receptor; CTL, cytotoxic T lymphocyte; IL, interleukin; NFAT, nuclear factor of activated T cells; nudt5, nudix hydrolase-5; PDGF, platelet-derived growth factor; PCNA, proliferative cellular nuclear antigen; wt, wild-type; 2-D, two-dimensional; 2-DE, two-dimensional gel electrophoresis; MHC, major histocompatibility complex. Back

* The work in the Seliger laboratory was supported by the Bundesministerium für Forschung, Bonn; Mainzer Forschungfördesung, Mainz; the Mildred Scheel-Stiftung, Bonn; and the Wilhelm Roux Program, Halle. The work in the Cologne laboratories were supported by the Deutsche Forschungsgemeinschaft, Bonn; the Wilhelm Sander-Stiftung, Munich; and the Deutsche Krebshilfe, Bonn.The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§§ To whom correspondence should be addressed: Inst. of Medical Immunology, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 2, 06112 Halle, Germany. Tel.: 49-345-5-57-40-54; Fax: 49-345-5-57-40-55; E-mail: Barbara.Seliger{at}medizin.uni-halle.de


    REFERENCES
 TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Alegre, M. L., Frauwirth, K. A., and Thompson, C. B. (2001) T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220 –228[CrossRef][Medline]

  2. Rothstein, D. M., and Sayegh, M. H. (2003) T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196, 85 –108[CrossRef][Medline]

  3. Sharpe, A. H., and Freeman, G. J. (2002) The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116 –126[CrossRef][Medline]

  4. Carreno, B. M., and Collins, M. (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29 –53[CrossRef][Medline]

  5. Lucas, P. J., Negishi, I., Nakayama, K., Fields, L. E., and Loh, D. Y. (1995) Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154, 5757 –5768[Abstract/Free Full Text]

  6. Kaech, S. M., Wherry, E. J., and Ahmed, R. (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251 –262[CrossRef][Medline]

  7. von Mehren, M., Arlen, P., Gulley, J., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S., Beard, M. T., Tsang, K. Y., Schlom, J., and Weiner, L. M. (2001) The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181 –1191[Abstract/Free Full Text]

  8. Schlom, J., Sabzevari, H., Grosenbach, D. W., and Hodge, J. W. (2003) A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Artif. Cells Blood Substit. Immobil. Biotechnol. 31, 193 –228[CrossRef][Medline]

  9. Raes, G., Van Ginderachter, J., Liu, Y. Q., Brys, L., Thielemans, K., De Baetselier, P., and Geldhof, A. (1998) Active anti-tumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model. Cancer Immunol. Immunother. 45, 257 –265[CrossRef][Medline]

  10. Tao, G., Hu, J., Zou, H., Lin, Q., Liu, F., Wu, Y., and Sun, Q. (2001) Therapeutic anti-tumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Chin. Med. J. (Engl. Ed.) 114, 623 –627[Medline]

  11. Jung, D., Jaeger, E., Cayeux, S., Blankenstein, T., Hilmes, C., Karbach, J., Moebius, U., Knuth, A., Huber, C., and Seliger, B. (1998) Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. Hum. Gene. Ther. 9, 53 –62[CrossRef][Medline]

  12. Jung, D., Hilmes, C., Knuth, A., Jaeger, E., Huber, C., and Seliger, B. (1999) Gene transfer of the co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand. J. Immunol. 50, 242 –249[CrossRef][Medline]

  13. Asai, T., Storkus, W. J., and Whiteside, T. L. (2000) Evaluation of the modified ELISPOT assay for {gamma} interferon production in cancer patients receiving anti-tumor vaccines. Clin. Diagn. Lab. Immunol. 7, 145 –154[Abstract/Free Full Text]

  14. McCutcheon, M., Wehner, N., Wensky, A., Kushner, M., Doan, S., Hsiao, L., Calabresi, P., Ha, T., Tran, T. V., Tate, K. M., Winkelhake, J., and Spack, E. G. (1997) A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods 210, 149 –166[CrossRef][Medline]

  15. Kellar, K. L., Kalwar, R. R., Dubois, K. A., Crouse, D., Chafin, W. D., and Kane, B. E. (2001) Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry 45, 27 –36[CrossRef][Medline]

  16. Carson, R. T., and Vignali, D. A. (1999) Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods 227, 41 –52[CrossRef][Medline]

  17. Kruse, N., Pette, M., Toyka, K., and Rieckmann, P. (1997) Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods 210, 195 –203[CrossRef][Medline]

  18. Diehn, M. A., Alizadeh, A., Rando, O. J., Liu, C. L., Stankunas, K., Botstein, D., Crabtree, G. R., and Brown, P. O. (2002) Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. U. S. A. 99, 11796 –11801[Abstract/Free Full Text]

  19. Chu, P., Pardo, J., Zhao, H., Li, C. C., Pali, E., Shen, M. M., Qu, K., Yu, S. X., Huang, B. C., Yu, P., Masuda, E. S., Molineaux, S. M., Kolbinger, F., Aversa, G., de Vries, J., Payan, D. G., and Liao, X. C. (2003) Systematic identification of regulatory proteins critical for T-cell activation. J. Biol. 2, 21[CrossRef][Medline]

  20. Riley, J. L., Mao, M., Kobayashi, S., Biery, M., Burchard, J., Cavet, G., Gregson, B. P., June, C. H., and Linsley, P. S. (2002) Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl. Acad. Sci. U. S. A. 99, 11790 –11795[Abstract/Free Full Text]

  21. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Ehring, B., Tampe, R., and Huber, C. (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res. 2, 1427 –1433[Abstract/Free Full Text]

  22. Kronfeld, K., Abken, H., and Seliger, B. (2005) B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int. J. Cancer, in press

  23. Lichtenfels, R., Ackermann. A., Kellner, R., and Seliger, B. (2001) Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line. Electrophoresis 22, 1801 –1809[CrossRef][Medline]

  24. Sobel, A. (1991) Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem. Sci. 16, 301 –305[CrossRef][Medline]

  25. Nagasaka, Y., Fijimoto, M., Arai, H., and Nakamura, K. (2002) Inhibition of heat-induced phosphorylation of stathmin by the bioflavonoid quercetin. Electrophoresis 23, 670 –673[CrossRef][Medline]

  26. Yang, H., Slupska, M. M., Wei, Y. F., Tai, J. H., Luther, W. M., Xia, Y. R., Shih, D. M., Chiang, J. H., Baikalov, C., Fitz-Gibbon, S., Phan, I. T., Conrad, A., and Miller, J. H. (2000) Cloning and characterization of a new member of the Nudix hydrolases from human and mouse. J. Biol. Chem. 275, 8844 –8853[Abstract/Free Full Text]

  27. Huang, J., Zhu, H., Haggarty, S. J., Spring, D. R., Hwang, H., Jin, F., Snyder, M., and Schreiber, S. L. (2004) Finding new components of the target or rapamycin (TOR) signalling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U. S. A. 101, 16594[Abstract/Free Full Text]

  28. Laurence, A., Astoul, E., Hanrahan, S., Totty, N., and Cantrell, D. (2004) Identification of pro-interleukin 16 as a novel target of MAP kinases in activated T lymphocytes. Eur. J. Immunol. 34, 587 –597[CrossRef][Medline]

  29. Wollscheid, B., von Haller, P. D., Yi, E., Donohoe, S., Vaughn, K., Keller, A., Nesvizhskii, A. I., Eng, J., Li, X. J., Goodlett, D. R., Aebersold, R., and Watts, J. D. (2004) Lipid raft proteins and their identification in T lymphocytes. Subcell. Biochem. 37, 121 –152[Medline]

  30. Stentz, F. B., and Kitabchi, A. E. (2004) Transcriptome and proteome expression in activated human CD4 and CD8 T-lymphocytes. Biochem. Biophys. Res. Commun. 324, 692 –696[CrossRef][Medline]

  31. Kawakami, T., Nagata, T., Muraguchi, A., and Nishimura, T. (2003) Proteomic approach to apoptotic thymus maturation. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 787, 223 –229[Medline]

  32. Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, R., Nadler, L. M., and Griffin, J. D. (1996) B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J. Immunol. 156, 1126 –1131[Abstract]

  33. Fields, P. E., Finch, R. J., Gray, G. S., Zollner, R., Thomas, J. L., Sturmhoefel, K., Lee, K., Wolf, S., Gajewski, R. F., and Fitch, F. W. (1998) B7-1 is a quantitatively stronger costimulus that B7-2 in the activation of naïve CD8+ TCR-transgenic T cells. J. Immunol. 161, 5268 –5275[Abstract/Free Full Text]

  34. Freeman, G. J., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J. W., Kim, J., Goldberg, J. M., Hathcock, K., and Laszlo, G.(1993) Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178, 2185 –2192[Abstract/Free Full Text]

  35. Healy, C. G., Simons, J. W., Carducci, M. A., DeWeese, T. L., Bartkowski, M., Tong, K. P., and Bolton, W. E. (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32, 109 –119[CrossRef][Medline]

  36. Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., and Thompson, C. B. (2002) The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769 –777[CrossRef][Medline]

  37. le Gouvello, S., Manceau, V., and Sobel, A. (1998) Serine 16 of stathmin as a cytosolic target for Ca2+/calmodulin-dependent kinase II after CD2 triggering of human T lymphocytes. J. Immunol. 161, 1113 –1122[Abstract/Free Full Text]

  38. Boss, V., Abbott, K. L., Wang, X. F., Pavlath, G. K., and Murphy, T. J. (1998) The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface receptors. J. Biol. Chem. 273, 19664 –19671[Abstract/Free Full Text]

  39. Fischer, W. H., and Schubert, D. (1996) Characterization of a novel platelet-derived growth factor-associated protein. J. Neurochem. 66, 2213 –2216[Medline]

  40. Gomez, M. F., Stevenson, A. S., Bonev, A. D., Hill-Eubanks, D. C., and Nelson, M. T. (2002) Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle. J. Biol. Chem. 277, 37756 –37764[Abstract/Free Full Text]

  41. Stacey, D. W. (2003) Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15, 158 –163[CrossRef][Medline]

  42. Cho, N. H., Kim, Y. T., and Kim, J. W. (2002) Alteration of cell cycle in cervical tumor associated with human papillomavirus: cyclin-dependent kinase inhibitors. Yonsei Med. J. 43, 722 –728[Medline]

  43. Blagosklonny, M. V., and Pardee, A. B. (2002) The restriction point of the cell cycle. Cell Cycle 1, 103 –110[Medline]

  44. Furukawa, Y. (2002) Cell cycle control genes and hematopoietic cell differentiation. Leuk. Lymphoma 43, 225 –231[CrossRef][Medline]

  45. Su, F., Hu, X., Jia, W., Gong, C., Song, E., and Hamar, P. (2003) Glutathione S transferase pi indicates chemotherapy resistance in breast cancer. J. Surg. Res. 113, 102[CrossRef][Medline]

  46. Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., Tafuri-Bladt, A., Brankow, D., Campbell, P., Chang, D., Chiu, L., Dai, T., Duncan, G., Elliott, G. S., Hui, A., McCabe, S. M., Scully, S., Shahinian, A., Shaklee, C. L., Van, G., Mak, T. W., and Senaldi, G. (1999) T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 827 –832[CrossRef][Medline]

  47. Gurbuxani, S., Singh Arya, L., Raina, V., Sazawal, S., Khattar, A., Magrath, I., Marie, J., and Bhargava, M. (2001) Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients. Cancer Lett. 167, 73 –83[CrossRef][Medline]

  48. Gorner, K., Holtorf, E., Odoy, S., Nuscher, B., Yamamoto, A., Regula, J. T., Beyer, K., Haass, C., and Kahle, P. J. (2004) Differential effects of Parkinson’s disease-associated mutations on stability and folding of DJ-1. J. Biol. Chem. 279, 6943 –6951[Abstract/Free Full Text]

  49. MacKeigan, J. P., Clements, C. M., Lich, J. D., Pope, R. M., Hod, Y., and Ting, J. P. (2003) Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDI{alpha}. Cancer Res. 63, 6928 –6934[Abstract/Free Full Text]

  50. Hod, Y., Pentyala, S. N., Whyard, T. C., and El-Maghrabi, M. R. (1999) Identification and characterization of a novel protein that regulates RNA-protein interaction. J. Cell. Biochem. 72, 435 –444[CrossRef][Medline]

  51. Nagakubo, D., Taira, T., Kitaura, H., Ikeda, M., Tamai, K., Iguchi-Ariga, S. M., and Ariga, H. (1997) DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231, 509 –513[CrossRef][Medline]

  52. Blow, J. J. (2003) A new role for Ran in ensuring precise duplication of chromosomal DNA. Cell 113, 2 –4[CrossRef][Medline]

  53. Neuwald, A. F., Kannan, N., Poleksic, A., Hata, N., and Liu, J. S. (2003) Ran’s C-terminal, basic patch, and nucleotide exchange mechanisms in light of a canonical structure for Rab, Rho, Ras, and Ran GTPases. Genome Res. 13, 673 –692[Abstract/Free Full Text]

  54. Manser, E. (2002) Small GTPases take the stage. Dev. Cell 3, 323 –328[CrossRef][Medline]

  55. Steggerda, S. M., and Paschal, B. M. (2002) Regulation of nuclear import and export by the GTPase Ran. Int. Rev. Cytol. 217, 41 –91[Medline]

  56. Cronauer, M. V., Schulz, W. A., Burchardt, T., Anastasiadis, A. G., de la Taille, A., Ackermann, R., and Burchardt, M. (2003) The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling. Int. J. Oncol. 23, 1095 –1102[Medline]

  57. Wilce, J. A., Leedman, P. J., and Wilce, M. C. (2002) RNA-binding proteins that target the androgen receptor mRNA. IUBMB Life 54, 345 –349[Medline]

  58. Mulholland, D. J., Read, J. T., Rennie, P. S., Cox, M. E., and Nelson, C. C. (2003) Functional localization and competition between the androgen receptor and T-cell factor for nuclear ß-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22, 5602 –5613[CrossRef][Medline]

  59. Chesire, D. R., and Isaacs, W. B. (2002) Ligand-dependent inhibition of ß-catenin/TCF signaling by androgen receptor. Oncogene 21, 8453 –8469[CrossRef][Medline]

  60. Benten, W. P., Becker, A., Schmitt-Wrede, H. P., and Wunderlich, F. (2002) Developmental regulation of intracellular and surface androgen receptors in T cells. Steroids 67, 925 –931[CrossRef][Medline]

  61. Faure, J., and Dagher, M. C. (2001) Interactions between Rho GTPases and Rho GDP dissociation inhibitor (Rho-GDI). Biochimie (Paris) 83, 409 –414[CrossRef][Medline]

  62. Gosser, Y. Q., Nomanbhoy, T. K., Aghazadeh, B., Manor, D., Combs, C., Cerione, R. A., and Rosen, M. K. (1997) C-terminal binding domain of Rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases. Nature 387, 814 –819[CrossRef][Medline]

  63. Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., Sedivy, J. M., and Kolch, W. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173 –177[CrossRef][Medline]

  64. Ojika, K., Mitake, S., Tohdoh, N., Appel, S. H., Otsuka, Y., Katada, E., and Matsukawa, N. (2000) Hippocampal cholinergic neurostimulating peptides (HCNP). Prog. Neurobiol. 60, 37 –83[CrossRef][Medline]

  65. Fu, Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., and Keller, E. T. (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95, 878 –889[Abstract/Free Full Text]

  66. Corbit, K. C., Trakul, N., Eves, E. M., Diaz, B., Marshall, M., and Rosner, M. R. (2003) Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 278, 13061 –13068[Abstract/Free Full Text]

  67. Vainberg, I. E., Lewis, S. A., Rommelaere, H., Ampe, C., Vandekerckhove, J., Klein, H. L., and Cowan, N. J. (1998) Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 93, 863 –873[CrossRef][Medline]

  68. Mori, K., Maeda, Y., Kitaura, H., Taira, T., Iguchi-Ariga, S. M., and Ariga, H. (1998) MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc. J. Biol. Chem. 273, 29794 –29800[Abstract/Free Full Text]

  69. Lim, R., and Zaheer, A. (1995) Phorbol ester stimulates rapid intracellular phosphorylation of glia maturation factor. Biochem. Biophys. Res. Commun. 211, 928 –934[CrossRef][Medline]

  70. Winkel, K. D., Kronin, V., Krummel, M. F., and Shortman, K. (1997) The nature of the signals regulating CD8 T cell proliferative responses to CD8{alpha}+ or CD8{alpha}– dendritic cells. Eur. J. Immunol. 27, 3350 –3359[Medline]

  71. Anderson, D. E., Ausubel, L. J., Krieger, J., Hollsberg, P., Freeman, G. J., and Hafler, D. A. (1997) Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones. J. Immunol. 159, 1669 –1675[Abstract]

  72. Kim, K. S., Denton, M. D., Chandraker, A., Knoflach, A., Milord, R., Waaga, A. M., Turka, L. A., Russell, M. E., Peach, R., and Sayegh, M. H. (2001) CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. J. Pathol. 158, 977 –986[Abstract/Free Full Text]





This Article
Abstract
Full Text (PDF)
All Versions of this Article:
M500194-MCP200v1
4/12/1876    most recent
Submit a response
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me when eLetters are posted
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Glossary
Copyright Permissions
Google Scholar
Articles by Kronfeld, K.
Articles by Seliger, B.
PubMed
PubMed Citation
Articles by Kronfeld, K.
Articles by Seliger, B.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education